ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1158

Development of Cut-off Values for High Disease Activity in Juvenile Idiopathic Arthritis Based On the Juvenile Arthritis Disease Activity Score

Alessandro Consolaro1, Stefano Lanni1, Sara Verazza1, Maria C. Gallo1, Marta Bertamino1, Giulia C. Varnier1, Serena Calandra2, Nicolino Ruperto3, Alberto Martini4 and Angelo Ravelli5, 1Pediatria II, Istituto Giannina Gaslini, Genova, Italy, 2University of Genova, Genova, Italy, 3Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, 4Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 5Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Activity score, juvenile idiopathic arthritis (JIA) and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: In the last decade, there have been major advances in the management of juvenile idiopathic arthritis (JIA), including the shift towards early aggressive interventions and the development of new therapeutic agents and combination treatment strategies. A reliable documentation of the advances in therapeutic effectiveness creates the need for validated and clinically useful criteria that describe precisely the clinical state of the patient. The study was aimed to determine cut-off values for the state of high disease activity (HDA) in JIA based on the Juvenile Arthritis Disease Activity Score (JADAS).

Methods: For the selection of cut-offs, data from a clinical database including 618 children with JIA followed between 2007 and 2011 were used. Patients were defined as being in HDA when one of the following  therapeutic interventions was prescribed: 1) start of methotrexate; 2) intraarticular corticosteroid therapy; 3) start of a biologic medication; 4) start of systemic corticosteroid therapy. Patients were defined as having low disease activity (LDA) when they were receiving no therapy or had therapy discontinued, tapered or left unchanged for > 1 year. For each patient, 1 visit in HDA and 1 visit in LDA were retained. Optimal JADAS cut-offs were determined by calculating the 25thpercentile of cumulative score distribution in patients with HDA and by assessing their ability to discriminate between the states of HDA and LDA through ROC curve analysis (including calculation of Youden index and fixed 90% specificity). Cross-validation of cut-offs  was performed in 490 JIA patients enrolled in the PRINTO methotrexate trial (Ruperto et al, A&R 2004;50:2191-201) and on 358 patients followed longitudinally at study centers for a median of 1.7 years, and was based on assessment of discriminative and predictive validity.

Results: The cut-offs were calculated separately for patients with oligoarticular and polyarticular course of joint disease (irrespective of ILAR category) owing to the different severity of these 2 JIA phenotypes. Complete clinical data were available for 258 visits of patients with oligoarthritis and 289 visits of patients with polyarthritis. JADAS-10 and JADAS-71 cut-offs were 7.6 for oligoarthritis and 10.6 for polyarthritis. JADAS-27 cutoffs were 7.7 for oligoarthritis and 8.9 for polyarthritis. Validation analyses showed that at baseline visit of methotrexate trial 94.7% of patients had a JADAS higher than the proposed cut-off for JADAS. At 6-month visit, the percentage of patients with a JADAS higher than the cut-off was 85.6% among nonresponders and 23.8% among responders. Evidence of predictive ability of the cut-offs was obtained by demonstrating that in the longitudinal patient sample, the percentage of patients with inactive disease or with a C-HAQ score of 0 at final visit was significantly lower among patients who had a JADAS above the cut-off value at first visit than among those who did not.

Conclusion: We developed the JADAS cut-offs for HDA in JIA. The cut-offs revealed strong discriminative and predictive ability in a clinical trial and are, therefore, potentially applicable in clinical practice, observational investigations, and therapeutic studies.


Disclosure:

A. Consolaro,
None;

S. Lanni,
None;

S. Verazza,
None;

M. C. Gallo,
None;

M. Bertamino,
None;

G. C. Varnier,
None;

S. Calandra,
None;

N. Ruperto,
None;

A. Martini,
None;

A. Ravelli,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-cut-off-values-for-high-disease-activity-in-juvenile-idiopathic-arthritis-based-on-the-juvenile-arthritis-disease-activity-score/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology